Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS
Study sponsor: Brainstorm-Cell Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2016-03Actual
Enrollment · participants48Actual
Source updated2024-06-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.